Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Multidrug resistance (MDR) significantly limits chemotherapy efficacy in cancer treatment.
• ATP binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, are major contributors to cancer MDR.
• Targeting ABC transporters is a key strategy to overcome MDR.

Purpose of the Study:

• To synthesize and evaluate a novel 5-cyano-6-phenylpyrimidin derivative (compound 479) for its ability to reverse MDR.
• To investigate the selective MDR reversal activity of compound 479 against specific ABC transporters.
• To elucidate the mechanism of action of compound 479 in overcoming MDR.

Main Methods:

• Synthesis of a novel 5-cyano-6-phenylpyrimidin derivative.
• In vitro evaluation of MDR reversal activity against ABCB1, ABCG2, ABCC1, and ABCC10 transporters.
• Mechanism studies including drug accumulation assays and ATPase activity measurements.
• In silico molecular docking studies to assess binding interactions.

Main Results:

• Compound 479 selectively reversed MDR mediated by ABCB1 and ABCG2, but not ABCC1 or ABCC10.
• 479 enhanced the intracellular accumulation of paclitaxel and mitoxantrone.
• Mechanism studies revealed that 479 inhibits transporter efflux function and stimulates ABCB1/ABCG2 ATPase activity.
• In silico analysis confirmed favorable binding interactions of 479 within the drug-binding pockets of ABCB1 and ABCG2.

Conclusions:

• Compound 479 is a potent dual inhibitor of ABCB1 and ABCG2, effectively reversing MDR.
• This novel derivative shows promise as a prototype for developing new MDR reversal agents.
• Targeting ABCB1 and ABCG2 with agents like compound 479 could enhance cancer chemotherapy outcomes.